Neil Hendron

Neil Hendron helps clients achieve their transactional objectives efficiently and effectively.

Neil works with companies at all stages of development and regularly advises on a wide range of corporate transactions - from advising established companies and investors on significant investments to working with spin-out and start-up companies on early stage fundraising. Neil regularly acts for international corporations and institutional investors on significant acquisitions and divestments and has particular experience in international private company M&A.

Neil enjoys helping clients achieve goals which are important to their business. Corporate transactional work can often be complex and Neil sees one of his main roles as trying to manage this complexity. An important part of achieving this is working with clients and spending time getting an understanding of their business and what matters most to them.


Understanding what makes a business tick, successfully delivering a transaction and having a happy client is the highlight of my job.

A particular highlight was acting on the sale of Opus Energy to Drax plc. Opus had been a client of the firm for over a decade and it was great to help the shareholders in Opus Energy realise a successful exit with the firm having worked with Opus for so many years.


Corporates (UK-based and international), private equity investors, venture capital funds and business owners.


  • Acting for the shareholders of Opus Energy in the sale of Opus Energy to Drax plc for over £340 million.
  • Acting for Equiom Group on a series of acquisitions as part of the implementation of its international expansion.
  • Acting for Greenko plc on the sale of Greenko Mauritius for $250 million.
  • Acting for AstraZeneca on the sale of Carpelsa to Genzyme for up to $300 million.
  • Acting for Prostrakan on the acquisition of Archimedes Pharma Limited (European-based specialty pharmaceutical company) for £230 million.
  • Acting for Star Capital Partners on its acquisition of Synergy Health Management Services for £50 million.
  • Acting for US-listed Dover Corporation on a number of its UK acquisitions.
  • Acting for the consortium of lead investors (including Imperial Innovations, SR One, Pfizer ventures, Roche and Sofinnova) on a £50 million funding round into Mission Therapeutics.
  • Acting for the consortium of lead investors (consisting of SR One, SV Life Sciences and Lundbeckfond Invest) on a £16.5 million series A financing of VHSquared Limited.